Autoimmune basis of glaucoma

Seminars in Ophthalmology

Volumn 26, Issue 4-5, 2011, Pages 278-281

  Shazly, Tarek A ^a,b   Aljajeh, Mouhab ^a   Latina, Mark A ^a  

^a MASSACHUSETTS EYE AND EAR INFIRMARY   (United States)

^b ASSIUT UNIVERSITY   (Egypt)

Author keywords

Aging; Glaucoma; Glia; Immune system; Oxidative stress; Retinal ganglion cell

Indexed keywords

AUTOANTIBODY; GLATIRAMER;

ADAPTIVE IMMUNITY; AUTOIMMUNITY; CELL SURVIVAL; DEGENERATIVE DISEASE; GLAUCOMA; HUMAN; IMMUNOREGULATION; INTRAOCULAR PRESSURE; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; RETINA GANGLION CELL; REVIEW;

AUTOIMMUNITY; GLAUCOMA; HUMANS; IMMUNE SYSTEM; OPTIC NERVE DISEASES; OXIDATIVE STRESS; RETINAL GANGLION CELLS;

EID: 80053515391     PISSN: 08820538     EISSN: 17445205     Source Type: Journal    
DOI: 10.3109/08820538.2011.588649     Document Type: Review

References (38)

1. Quigley HA. Open-angle glaucoma. N Engl J Med. 1993;328:1097-1106 (Pubitemid 23097800)
2. Quigley HA. Number of people with glaucoma worldwide. Br J Ophthalmol. 1996;80:389-393 (Pubitemid 26158268)
3. Wax MB. Is there a role for the immune system in glaucomatous optic neuropathy? Curr Opin Ophthalmol. 2000;11:145-150 (Pubitemid 30164037)
4. Wax MB. Glaucoma: An autoimmune disease in some patients? Research to Prevent Blindness. 2000
5. Tezel G, Seigel GM, Wax MB. Autoantibodies to small heat shock proteins in glaucoma. Invest Ophthalmol Vis Sci. 1998;39:2277-2287 (Pubitemid 28485639)
6. Grus FH, Joachim SC, Hoffmann EM, et al. Complex autoantibody repertoires in patients with glaucoma. Mol Vis. 2004;10:132-137 (Pubitemid 38628967)
7. Joachim SC, Pfeiffer N, Grus FH. Autoantibodies in patients with glaucoma: A comparison of IgG serum antibodies against retinal, optic nerve, and optic nerve head antigens. Graefes Arch Clin Exp Ophthalmol. 2005;243: 817-823 (Pubitemid 41300425)
8. Grus FH, Joachim SC, Bruns K, et al. Serum autoantibodies to alpha-fodrin are present in glaucoma patients from Germany and the United States. Invest Ophthalmol Vis Sci. 2006;47:968-976 (Pubitemid 46768329)
9. Weinreb RN, Khaw PT. Primary open-angle glaucoma. Lancet. 2004;363:1711-1720 (Pubitemid 38670330)
10. Burgoyne CF, Downs JC, Bellezza AJ, et al. The optic nerve head as a biomechanical structure: A new paradigm for understanding the role of IOP-related stress and strain in the pathophysiology of glaucomatous optic nerve head damage. Prog Retin Eye Res. 2005;24:39-73 (Pubitemid 39535155)
11. Sigal IA, Flanagan JG, Ethier CR. Factors influencing optic nerve head biomechanics. Invest Ophthalmol Vis Sci. 2005;46:4189-4199 (Pubitemid 44264622)
12. Tezel G, Wax MB. Hypoxia-inducible factor 1alpha in the glau-comatous retina and optic nerve head. Arch Ophthalmol. 2004; 122:1348-1356 (Pubitemid 39180857)
13. Tezel G, Hernandez R, Wax MB. Immunostaining of heat shock proteins in the retina and optic nerve head of normal and glaucomatous eyes. Arch Ophthalmol. 2000;118:511-518 (Pubitemid 30203146)
14. Quigley HA, Maumenee AE. Long-term follow-up of treated open-angle glaucoma. Am J Ophthalmol. 1979;87:519-525 (Pubitemid 9125609)
15. Kass M.A., Heuer DK, Higginbotham EJ, et al. The Ocular Hypertension Treatment Study: A randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol. 2002;120:701-713; discussion 829-730 (Pubitemid 34620348)
16. Leske MC, Heijl A, Hussein M, et al. Factors for glaucoma progression and the effect of treatment: The early manifest glaucoma trial. Arch Ophthalmol. 2003;121:48-56 (Pubitemid 36401765)
17. Johnson EC, Cepurna WO, Jia L, et al. The use of cyclodialysis to limit exposure to elevated intraocular pressure in rat glaucoma models. Exp Eye Res. 2006;83:51-60 (Pubitemid 43783246)
18. Nickells RW, Schlamp CL, Li Y, et al. Surgical lowering of elevated intraocular pressure in monkeys prevents progression of glaucoma-tous disease. Exp Eye Res. 2007;84:729-736 (Pubitemid 46400639)
19. Heijl A, Leske MC, Bengtsson B, et al. Reduction of intraocular pressure and glaucoma progression: Results from the Early Manifest Glaucoma Trial. Arch Ophthalmol. 2002;120:1268-1279 (Pubitemid 36105431)
20. Wax MB, Tezel G. Immunoregulation of retinal ganglion cell fate in glaucoma. Exp Eye Res. 2009 Apr;88(4):825-30
21. Wax MB, Tezel G, Saito I, et al. Anti-Ro/SS-A positivity and heat shock protein antibodies in patients with normal-pressure glaucoma. Am J Ophthalmol. 1998;125:145-157 (Pubitemid 28081291)
22. Cartwright MJ, Grajewski, AL, Friedberg ML, Anderson DR, Richards DW. Immune-related disease and normaltension glaucoma. A case-control study. Arch. Ophthalmol. 1992;110:500-502
23. Maruyama I, Ohguro H, Ikeda Y. Retinal ganglion cells recognized by serum autoantibody against gamma-enolase found in glaucoma patients. Invest Ophthalmol Vis Sci 2000; 41:1657-1665 (Pubitemid 30354333)
24. Yang J, Tezel G, Patil RV, Romano C, Wax MB. Serum autoantibody against glutathione S-transferase in patients with glaucoma. Invest Ophthalmol Vis Sci. 2001; 42:1273-1276 (Pubitemid 32381969)
25. Kremmer S, Kreuzfelder E, Klein R, Bontke N, Henneberg-Quester KB, Steuhl K.P., Grosse-Wilde H. Antiphosphatidylserine antibodies are elevated in normal tension glaucoma. Clin Exp Immunol. 2001;125:211-215 (Pubitemid 32758430)
26. Ikeda Y, Maruyama I, Nakazawa M, Ohguro H. Clinical significance of serum antibody against neuron-specific enolase in glaucoma patients. Jpn J Ophthalmol. 2002;46:13-17 (Pubitemid 34195467)
27. Tezel G, Edward DP, Wax MB. Serum autoantibodies to optic nerve head glycosaminoglycans in patients with glaucoma. Arch Ophthalmol. 1999;117:917-924 (Pubitemid 29330779)
28. Avrameas S. Natural autoantibodies: From "horror autotoxicus" to "gnothi seauton." Immunol Today. 2001;12:154-159
29. Li WH, Zhao J, Li HY, Liu H, Li AL, Wang HX, Wang J, He K, Liang B, Yu M, Shen BF, Zhang XM. Proteomics-based identification of autoantibodies in the sera of healthy Chinese individuals from Beijing. Proteomics 2006;6:4781-4789 (Pubitemid 44369057)
30. Tezel G. The immune response in glaucoma: A perspective on the roles of oxidative stress. Exp Eye Res. 2010 Aug 13
31. Stevens B, Allen NJ, Vazquez L.E., Howell GR, Christopherson KS, Nouri N, Micheva KD, Mehalow AK, Huberman AD, Stafford B, Sher A, Litke A.M., Lambris JD, Smith SJ, John SW, Barres BA. The classical complement cascade mediates CNS synapse elimination. Cell. 2007 Dec 14;131(6):1164-78 (Pubitemid 350235022)
32. Spencer PS, Schaumburg HH. Ultrastructural studies of the dying-back process. IV. Differential vulnerability of PNS and CNS fibers in experimental central-peripheral distal axonopathies. J Neuropathol Exp Neurol. 1977 Mar- Apr;36(2):300-20 (Pubitemid 8066924)
33. Morfini GA, Burns M, Binder LI, Kanaan NM, LaPointe N, Bosco DA, Brown RH Jr., Brown H, Tiwari A, Hayward L, Edgar J, Nave KA, Garberrn J, Atagi Y, Song Y, Pigino G, Brady ST. Axonal transport defects in neurodegenerative diseases. J Neurosci. 2009 Oct 14;29(41):12776-86
34. Schwartz M. Neurodegeneration and neuroprotection in glaucoma: development of a therapeutic neuroprotective vaccine: The Friedenwald lecture. Invest Ophthalmol Vis Sci. 2003;44:1407-1411 (Pubitemid 36378560)
35. Schwartz M. Modulating the immune system: A vaccine for glaucoma? Can J Ophthalmol. 2007;42:439-441 (Pubitemid 46932039)
36. Bakalash S, Kessler A, Mizrahi T, et al. Antigenic specificity of immunoprotective therapeutic vaccination for glaucoma. Invest Ophthalmol Vis Sci. 2003;44:3374-3381 (Pubitemid 36909773)
37. Schwartz M. Vaccination for glaucoma: Dream or reality? Brain Res Bull. 2004;62:481-484
38. Grus FH, Joachim SC, Wuenschig DD, Rieck J, Pfeiffer N. Autoimmunity and glaucoma. J. Glaucoma 2008;17:79-84 (Pubitemid 351321483)